Using compression therapy to prevent nerve damage in breast cancer patients
Prevention of Chemotherapy-induced Polyneuropathy (CIPN) Using Compressive Therapy
This study is testing if wearing special compression gloves and knee socks can help breast cancer patients avoid nerve damage caused by chemotherapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | Female |
| Sponsor | Masaryk Memorial Cancer Institute Academic / other |
| Drugs / interventions | Chemotherapy |
| Locations | 1 site (Brno) |
| Trial ID | NCT06823440 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of compressive therapy, specifically using surgical gloves and compression knee socks, to prevent chemotherapy-induced peripheral neuropathy (CIPN) in patients undergoing treatment for breast cancer. CIPN is a common and debilitating side effect of certain chemotherapy drugs, which can significantly affect patients' quality of life. The study will assess the efficacy of this intervention through quality-of-life questionnaires, hand strength and coordination tests, and laboratory analyses to identify predictive markers of neuropathy. The goal is to enhance CIPN prevention and potentially integrate this method into clinical practice.
Who should consider this trial
Good fit: Ideal candidates for this study are breast cancer patients aged 18-70 who are receiving (neo)adjuvant treatment with paclitaxel and have an ECOG performance status of 0-2.
Not a fit: Patients with metastatic disease, prior neuropathy, or those who have received certain chemotherapy treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the incidence of CIPN, improving the quality of life for breast cancer patients undergoing chemotherapy.
How similar studies have performed: Previous research has indicated that compression therapy can effectively reduce CIPN, suggesting that this approach may be promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18-70 years at the time of signing the informed consent (IC). * Signed informed consent. * Breast cancer stages I-III * ECOG performance status 0-2. * (Neo)adjuvant treatment with paclitaxel weekly. Exclusion Criteria: * Metastatic disease. * History of neuropathy/vasculopathy and its pharmacological treatment. * Type I or II diabetes. * Stroke within the last 6 months. * Prior treatment with taxanes and/or cisplatin derivatives. * Peripheral arterial ischemia.
Where this trial is running
Brno
- Masaryk Memorial Cancer Institute — Brno, Czechia (Recruiting)
Study contacts
- Principal investigator: Tatiana Ciprova, MBA — Masaryk Memorial Cancer Institute
- Study coordinator: Martina Lojova, Ph.D.
- Email: martina.lojova@mou.cz
- Phone: +420543136232
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.